Lactobacillus rhamnosus

Lacticaseibacillus rhamnosus

Entire Monograph

Reported Uses

NOTE: see Herb & Supplement Effectiveness Rating Definitions table
abdominal pain [Insufficient Evidence]
ADHD [Insufficient Evidence]
allergic rhinitis [Insufficient Evidence]
aphthous ulcer (canker sores) [Insufficient Evidence]
atopic dermatitis (eczema) [Possibly Effective]
atopic disease prevention [Possibly Effective]
bacterial vaginosis [Insufficient Evidence]
bipolar disorder [Insufficient Evidence]
C. difficile infection prevention [Insufficient Evidence]
cancer [Insufficient Evidence]
candidiasis, oropharyngeal [Insufficient Evidence]
candidiasis, vulvovaginal [Insufficient Evidence]
child development [Insufficient Evidence]
cognitive decline, age-related [Insufficient Evidence]
cognitive function [Insufficient Evidence]
cognitive impairment [Insufficient Evidence]
colic [Insufficient Evidence]
common cold [Insufficient Evidence]
constipation [Insufficient Evidence]
COVID-19 [Insufficient Evidence]
critical illness (trauma) [Possibly Ineffective]
Crohn disease [Insufficient Evidence]
cystic fibrosis [Insufficient Evidence]
dental caries prevention [Insufficient Evidence]
dental plaque [Insufficient Evidence]
denture stomatitis [Insufficient Evidence]
diabetes [Insufficient Evidence]
diarrhea [Insufficient Evidence]
diarrhea, antibiotic-associated [Possibly Effective]
diarrhea, chemo-related [Insufficient Evidence]
diarrhea, malnourishment-related [Insufficient Evidence]
diarrhea, rotaviral [Insufficient Evidence]
gingivitis [Insufficient Evidence]
group B streptococcal colonization [Insufficient Evidence]
H. pylori infection [Insufficient Evidence]
HIV/AIDS [Insufficient Evidence]
HTN [Insufficient Evidence]
hypercholesterolemia [Insufficient Evidence]
IBS [Insufficient Evidence]
lactose intolerance [Insufficient Evidence]
malnutrition [Insufficient Evidence]
metabolic syndrome [Insufficient Evidence]
necrotizing enterocolitis [Insufficient Evidence]
neurogenic bladder [Insufficient Evidence]
metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
obesity [Insufficient Evidence]
osteoarthritis [Insufficient Evidence]
otitis media [Insufficient Evidence]
peanut allergy [Possibly Ineffective]
periodontitis [Insufficient Evidence]
polycystic ovary syndrome [Insufficient Evidence]
postop bowel function [Insufficient Evidence]
postop infection [Insufficient Evidence]
postop recovery [Insufficient Evidence]
postpartum depression [Insufficient Evidence]
pouchitis [Insufficient Evidence]
respiratory infections [Insufficient Evidence]
rheumatoid arthritis [Insufficient Evidence]
short bowel syndrome [Insufficient Evidence]
small intestinal bacterial overgrowth (SIBO) [Insufficient Evidence]
stress [Insufficient Evidence]
traveler's diarrhea prophylaxis [Insufficient Evidence]
ulcerative colitis [Insufficient Evidence]
UTI [Insufficient Evidence]
ventilator-associated pneumonia prevention [Possibly Ineffective]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note

[formulation clarification]
Info: uses and doses represent various probiotic-containing products; other Lacticaseibacillus species exist, but are not included; prior name was Lactobacillus rhamnosus, reclassified as Lacticaseibacillus; select proprietary products noted below

[Culturelle products]
Info: each capsule contains 10-20 billion CFUs L. rhamnosus GG; each chewable tablet contains 2.5-10 billion CFUs L. rhamnosus GG; each powder packet contains 2.5-5 billion CFUs L. rhamnosus GG; other multi-ingredient products exist

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

atopic dermatitis (eczema) tx

[Possibly Effective]
Dose: 30 billion CFUs/kg/day PO qd in infants (L. rhamnosus GG); Alt: 1 billion CFUs PO qd in patients <2 yo (L. rhamnosus LOCK 0900 25%, LOCK 0908 25% plus other probiotics); 20 billion CFUs PO bid in patients 1-13 yo (L. rhamnosus 19070-2 plus other probiotics); 10 billion CFUs PO qd in patients 1-12 yo (L. rhamnosus IDCC 3201); 3 billion CFUs PO qd (L. rhamnosus LRH020 plus other probiotics); 10 billion CFUs PO qd in patients 6-36 mo (L. rhamnosus GG)

atopic dermatitis (eczema) prevention

[Possibly Effective]
Dose: 6 billion CFUs PO qd (L. rhamnosus HN001); Alt: 2 billion CFUs PO qd (L. rhamnosus GG plus other probiotics); 2 billion CFUs PO qd (L. rhamnosus LPR plus other probiotics); 105 billion CFUs PO qd (L. rhamnosus GG plus other probiotics); Info: may start tx in pregnant patients at 32-36 wk gestation, then continue until 2-6mo postpartum, then may continue 2-6 billion CFUs PO qd in infants x2-24 mo after birth

atopic disease prevention

[Possibly Effective]
Dose: 10-20 billion CFUs PO qd (L. rhamnosus GG); Alt: 6 billion CFUs PO qd (L. rhamnosus HN001); Info: for infants with family history of atopy; start tx in pregnant patients 2-5wk before delivery, then continue in infants x3-36 mo after birth

bacterial vaginosis

[Insufficient Evidence (PO route)]
Dose: 4 billion CFUs/day PO divided qd-bid (L. rhamnosus GR-1 plus other probiotics); Info: used with metronidazole or tinidazole

[Insufficient Evidence (PV route)]
Dose: 200 million-2 billion CFUs PV qd x10 days (L. rhamnosus Lbp PB01-DSM 14870 plus other probiotics); Start: after clindamycin 2% vaginal cream x7 days

bipolar disorder

[Insufficient Evidence]
Dose: 100 million CFUs PO qd (L. rhamnosus GG plus other probiotics)

C. difficile infection prevention

[Insufficient Evidence]
Dose: 50-100 billion CFUs PO qd x5 days (L. rhamnosus CLR2 plus other probiotics); Info: used with antibiotics

candidiasis, vulvovaginal

[Insufficient Evidence]
Dose: 1 billion CFUs suppository PV bid x7 days (L. rhamnosus GG); Info: used with conventional tx

cognitive decline, age-related

[Insufficient Evidence]
Dose: 10 billion CFUs PO qd (L. rhamnosus GG)

cognitive impairment

[Insufficient Evidence]
Dose: 10 billion CFUs PO qd (L. rhamnosus GG)

colic

[Insufficient Evidence]
Dose: 250 million CFUs PO qd (L. rhamnosus plus other probiotics); Alt: 5 billion CFUs PO qd (L. rhamnosus ATCC 53103); Info: for infants 2-12 wk

dental caries prevention, adult patients

[Insufficient Evidence]
Dose: 200 million CFUs PO qd (L. rhamnosus LB21); Info: used with or without fluoride

dental caries prevention, peds patients

[Insufficient Evidence]
Dose: 21-292 million CFUs PO qd (L. rhamnosus GG ATCC 53103); Info: for patients 1-6 yo

dental plaque, adult patients

[Insufficient Evidence]
Dose: 4 billion CFUs lozenge PO qd (L. rhamnosus GG ATCC 53103 plus other probiotics)

dental plaque, peds patients

[Insufficient Evidence]
Dose: 1.84 billion CFUs lozenge PO bid (L. rhamnosus GG plus other probiotics); Info: for patients 13-15 yo

diabetes mellitus, type 2

[Insufficient Evidence]
Dose: 111 billion CFUs PO qd (L. rhamnosus plus other probiotics)

diarrhea prevention, peds patients

[Insufficient Evidence]
Dose: 6 billion CFUs PO bid in patients 1-36 mo (L. rhamnosus GG); Alt: 37 billion CFUs PO qd in patients 6-24 mo (L. rhamnosus GG)

diarrhea, antibiotic-associated, adult patients

[Possibly Effective]
Dose: 6-40 billion CFUs PO qd (L. rhamnosus GG); Alt: 100 billion CFUs PO qd (L. rhamnosus CLR2 plus other probiotics); 8 billion CFUs PO qd (L. rhamnosus R0011 plus other probiotics); 5 billion CFUs PO bid (L. rhamnosus NIZO 3689 plus other probiotics)

diarrhea, antibiotic-associated, peds patients

[Possibly Effective]
Dose: 10-20 billion CFUs PO qd (L. rhamnosus GG); Alt: 20 billion CFUs PO bid (L. rhamnosus GG); Info: used with conventional tx

diarrhea, chemo-related

[Insufficient Evidence]
Dose: 10-20 billion CFUs/day PO divided bid (L. rhamnosus GG)

diarrhea, rotaviral, peds patients

[Insufficient Evidence]
Dose: 10-100 billion CFUs/125 g fermented milk PO bid (L. rhamnosus GG); Alt: 10-100 billion CFUs freeze-dried powder PO bid (L. rhamnosus GG); 3 billion CFUs PO bid (L. rhamnosus GG)

gingivitis, adult patients

[Insufficient Evidence]
Dose: 4 billion CFUs lozenge PO qd (L. rhamnosus GG ATCC 53103 plus other probiotics)

gingivitis, peds patients

[Insufficient Evidence]
Dose: 1.84 billion CFUs lozenge PO bid (L. rhamnosus GG plus other probiotics); Info: for patients 13-15 yo

group B streptococcal colonization

[Insufficient Evidence]
Dose: 4 billion CFUs PO qd (L. rhamnosus GR-1 plus other probiotics); Info: start tx in pregnant patient at 35-37 wk gestation, then continue until delivery

H. pylori infection

[Insufficient Evidence]
Dose: 100 million-10 billion CFUs PO bid x14 days (L. rhamnosus GG plus other probiotics); Info: used with standard tx

IBS

[Insufficient Evidence]
Dose: 10 billion CFUs/day PO divided bid (L. rhamnosus plus other probiotics); Alt: 2.5 billion CFUs PO bid (L. rhamnosus LR110 plus other probiotics)

lactose intolerance

[Insufficient Evidence]
Dose: 5 billion CFUs PO qd (L. rhamnosus HN001 plus other probiotics)

metabolic dysfunction-associated steatotic liver disease, peds patients

[Insufficient Evidence]
Dose: 13 billion CFUs PO qd (L. rhamnosus DSMZ 21690 plus other probiotics)

obesity, adult patients

[Insufficient Evidence]
Dose: 162 million CFUs PO bid (L. rhamnosus)

obesity, peds patients

[Insufficient Evidence]
Dose: 20 billion CFUs PO qd (L. rhamnosus HN001 plus other probiotics); Info: for childhood prevention; start tx in pregnant patient from early gestation, then continue until 6mo postpartum

polycystic ovary syndrome

[Insufficient Evidence]
Dose: 10 billion CFUs PO bid (L. rhamnosus UBLR-58 plus other probiotics); Start: 10 billion CFUs PO qd x2mo (L. rhamnosus UBLR-58 plus other probiotics)

postop bowel function

[Insufficient Evidence]
Dose: 6 million CFUs PO q12h (L. rhamnosus GG); Start: day of surgery

postop recovery

[Insufficient Evidence]
Dose: 6 million CFUs PO q12h (L. rhamnosus GG); Start: day of surgery

postpartum depression

[Insufficient Evidence]
Dose: 6 billion CFUs PO qd (L. rhamnosus HN001); Start: 14-16 wk gestation

respiratory infections, adult patients

[Insufficient Evidence]
Dose: 2 billion CFUs PO qd (L. rhamnosus GG plus other probiotics)

respiratory infections, peds patients

[Insufficient Evidence]
Dose: 130-260 million CFUs PO qd (L. rhamnosus GG); Info: for patients 1-6 yo

traveler's diarrhea prophylaxis

[Insufficient Evidence]
Dose: 2 billion CFUs PO qd (L. rhamnosus GG); Info: start tx 2 days before trip, continue until end of trip

UTI prevention, adult patients

[Insufficient Evidence (PO route)]
Dose: 1 billion CFUs PO bid (L. rhamnosus GR-1 plus other probiotics)

[Insufficient Evidence (PV route)]
Dose: 1.6 billion CFUs/0.5 g suppository PV 2x/wk x2wk, then qmo (L. rhamnosus plus other probiotics); Alt: 100 billion CFUs/mL PV 2x/wk (L. rhamnosus)

UTI prevention, peds patients

[Insufficient Evidence]
Dose: 25 mg/kg/dose PO bid (L. rhamnosus plus other probiotics); Max: 1000 mg/day; Info: for patients 4 mo-5 yo